List of Excipients in Branded Drug XHANCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
OptiNose US Inc	XHANCE	fluticasone propionate	71143-375	BENZALKONIUM CHLORIDE
OptiNose US Inc	XHANCE	fluticasone propionate	71143-375	CARBOXYMETHYLCELLULOSE SODIUM
OptiNose US Inc	XHANCE	fluticasone propionate	71143-375	CELLULOSE, MICROCRYSTALLINE
OptiNose US Inc	XHANCE	fluticasone propionate	71143-375	DEXTROSE
OptiNose US Inc	XHANCE	fluticasone propionate	71143-375	EDETATE DISODIUM

Xhance Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Xhance is a fluticasone propionate nasal spray that uses Optinose’s exhalation delivery system to deposit drug higher and deeper in the nasal cavity than conventional nasal sprays. Its commercial value depends primarily on the device, delivery method, broad chronic rhinosinusitis indication, and recurring prescription use. The excipient strategy is comparatively conventional but creates opportunities in preservative reduction, suspension stability, device compatibility, supply resilience, and differentiated follow-on products.

What is Xhance and how does its formulation work?

Xhance contains fluticasone propionate, a poorly water-soluble corticosteroid, at 93 micrograms per actuation. The product is administered through a nosepiece while the patient exhales through a mouthpiece. The exhaled air helps close the soft palate and directs the aerosolized suspension into the nasal passages and sinus ostia.

The product’s formulation and device work as an integrated delivery system. Excipient selection must support:

• Uniform suspension of micronized fluticasone propionate
• Consistent delivered dose during shaking and actuation
• Chemical stability during the product’s shelf life
• Low irritation in chronically inflamed nasal tissue
• Compatibility with the pump, actuator and exhalation pathway
• Microbiological control in a multidose aqueous product
• Reliable plume and particle-size performance

Xhance is approved in the United States for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps in adults. The expanded indication increased the addressable market beyond patients with visible polyps. [1,2]

What excipients are used in Xhance?

The Xhance prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation function
Microcrystalline cellulose	Suspending and rheology-modifying agent
Carboxymethylcellulose sodium	Suspending polymer and viscosity modifier
Dextrose	Tonicity and formulation-balance agent
Benzalkonium chloride	Antimicrobial preservative
Polysorbate 80	Wetting and dispersion aid
Disodium edetate	Chelating agent and preservative-support excipient
Purified water	Aqueous vehicle

The formulation is a suspension rather than a simple aqueous solution. Fluticasone propionate’s low aqueous solubility makes particle control, wetting and suspension uniformity central to dose delivery.

The exact quantitative composition, particle-size distribution, manufacturing controls and device settings are not fully disclosed in the public prescribing information. Those elements can remain important trade secrets even where the qualitative excipient list is public.

Why are the Xhance excipients commercially important?

The excipients are commercially important because they determine whether the product can deliver a reproducible dose through a specialized nasal device. A conventional nasal suspension can tolerate a different balance of viscosity, sedimentation and redispersibility because its target deposition zone is different. Xhance must maintain consistent performance while the patient generates exhaled airflow through the device.

Three formulation risks are central:

1. Sedimentation and redispersion. Micronized corticosteroid particles must redisperse after storage and routine handling.
2. Pump-dose uniformity. Changes in viscosity, wetting or particle aggregation can affect emitted dose.
3. Nasal tolerability. Preservatives and surfactants may contribute to irritation, dryness or epistaxis in chronic-use patients.

The commercial opportunity is therefore less likely to come from replacing a single excipient and more likely to come from improving the complete suspension system.

How does Xhance’s excipient strategy compare with conventional nasal sprays?

Xhance differs from many conventional intranasal corticosteroids because its clinical differentiation comes from delivery location rather than a novel active ingredient.

Attribute	Xhance	Conventional fluticasone or steroid nasal spray
Active ingredient	Fluticasone propionate	Often fluticasone, mometasone or budesonide
Formulation type	Aqueous suspension	Aqueous suspension or solution
Delivery system	Exhalation delivery device	Standard nasal pump
Primary differentiation	Deposition in higher nasal and sinus regions	Broad nasal spray distribution
Preservative strategy	Multidose preserved product	Varies by product
Excipient opportunity	Device-compatible suspension optimization	Stability, comfort and preservative optimization
Main substitution risk	Generic or alternative device-based steroid	Lower-cost conventional nasal steroids

Xhance’s excipient system cannot be evaluated independently from the exhalation delivery device. A follow-on product with the same active ingredient and excipient list could still fail to reproduce the same clinical or deposition profile without equivalent device performance.

What formulation patents protect Xhance?

Publicly available intellectual-property protection for Xhance has centered on the exhalation delivery system, nasal deposition, treatment methods and related product configurations. The formulation may also be protected through patent claims directed to suspension composition, particle characteristics, dosing and device-product combinations.

The practical protection hierarchy is likely:

1. Exhalation delivery device architecture
2. Device use and nasal deposition methods
3. Fluticasone propionate product configurations
4. Suspension characteristics and dose uniformity
5. Manufacturing controls and device integration
6. Regulatory exclusivity and confidential know-how

An excipient substitution does not automatically avoid patent infringement. A patent can cover a concentration range, viscosity range, particle-size range, suspension system, device combination or method of use even if the substituted excipient is different.

The most relevant freedom-to-operate questions for a competing product are:

• Whether the product uses the same or an equivalent exhalation pathway
• Whether the active-particle size and suspension properties fall within claim scope
• Whether the formulation uses protected polymer or surfactant combinations
• Whether the proposed label overlaps protected chronic rhinosinusitis methods
• Whether the device and actuator reproduce claimed airflow or deposition parameters

When does Xhance lose exclusivity?

Xhance does not have a single exclusivity date because regulatory exclusivity, Orange Book patents, pediatric exclusivity and device-related intellectual property can expire at different times.

Protection category	Xhance status
Original U.S. approval	FDA approval in 2017 for nasal polyps
Expanded indication	Chronic rhinosinusitis with or without nasal polyps approved in 2024
New chemical entity exclusivity	Not applicable to fluticasone propionate
Regulatory exclusivity	Primarily patent-dependent; no NCE exclusivity
Orange Book patents	Must be reviewed against the current FDA listing
Pediatric exclusivity	Depends on FDA-listed pediatric studies and grants
Device protection	May extend beyond active-ingredient exclusivity
Generic pathway	Potentially ANDA, 505(b)(2), or device-linked combination-product pathway

Because fluticasone propionate is an established active ingredient, Xhance’s commercial protection is more dependent on formulation, delivery technology, method-of-use claims, patents and product-specific regulatory requirements than on new chemical entity exclusivity.

What is the Orange Book status of Xhance?

Xhance is a drug-device combination product. Its Orange Book position must be assessed together with the FDA-listed patents and the product’s reference-listed-drug designation.

An abbreviated new drug application applicant could face several barriers:

• Demonstrating pharmaceutical equivalence to the reference suspension
• Demonstrating bioequivalence for a locally acting nasal product
• Reproducing spray-pattern and particle-size characteristics
• Matching device operation and emitted dose
• Addressing any listed method-of-use patents
• Certifying against listed patents under Paragraph I, II, III or IV

For locally acting nasal products, in vitro characterization can be central, but FDA may also require additional comparative studies depending on the product, device and proposed formulation. A different excipient system could create a 505(b)(2) pathway rather than a straightforward ANDA pathway if the applicant cannot establish the required sameness.

Which companies could challenge Xhance?

The most credible competitors fall into four groups:

Generic nasal corticosteroid manufacturers

Companies with experience in generic fluticasone propionate, fluticasone furoate, mometasone or budesonide products have the strongest formulation and regulatory capabilities. Relevant commercial participants in the broader nasal corticosteroid market include large generic manufacturers and specialty pharmaceutical companies with nasal-device capabilities.

A standard generic nasal spray would not necessarily be substitutable for Xhance because the delivery system and deposition profile differ. Its competitive impact would be greater in patients who do not require enhanced sinus deposition.

505(b)(2) developers

A 505(b)(2) sponsor could develop:

• A modified fluticasone suspension
• A preservative-free or lower-preservative version
• A new exhalation or airflow-assisted nasal device
• A different corticosteroid using a comparable deposition strategy
• A higher-dose or longer-duration formulation

This pathway may offer more flexibility than an ANDA but may require clinical or comparative-performance studies.

Device manufacturers and specialty developers

Device companies could partner with an established corticosteroid manufacturer to create an exhalation-assisted nasal product. The main barrier is not only device manufacture. It is demonstrating that the device produces consistent regional deposition and clinically relevant outcomes.

Large respiratory and allergy companies

Companies with established nasal, respiratory or biologic franchises could compete through broader chronic rhinosinusitis portfolios. Biologics such as dupilumab, omalizumab and mepolizumab compete for severe chronic rhinosinusitis patients with nasal polyps, although they are not direct formulation substitutes. [3-5]

What commercial opportunities exist for Xhance excipients?

1. Preservative-free or reduced-preservative reformulation

Benzalkonium chloride is an established nasal preservative, but chronic exposure can raise tolerability concerns. A preservative-free multidose system would require a validated microbiological control strategy, such as:

• Sterile manufacturing
• A container-closure system with microbial protection
• A one-way valve or protected fluid path
• A unit-dose or low-bioburden architecture
• Alternative preservation technology

A preservative-free Xhance could support premium positioning if it improves nasal comfort or reduces treatment discontinuation. The device would need redesign or qualification because the current multidose format may depend on benzalkonium chloride and related preservative controls.

2. New suspending systems

Microcrystalline cellulose and carboxymethylcellulose sodium are functional but may create viscosity, sedimentation or spray-performance constraints. Alternative systems could use:

• Different cellulose derivatives
• Polymeric suspending agents with narrower rheology profiles
• Structured vehicles that improve redispersion
• Surface-modified drug particles
• Controlled flocculation approaches

The commercial goal would be tighter dose uniformity with less shaking dependence and lower risk of nozzle blockage.

3. Improved wetting and particle dispersion

Polysorbate 80 supports wetting and dispersion but may be evaluated for oxidation, peroxide formation and compatibility with micronized corticosteroid particles. Alternative surfactants or particle-engineering approaches could improve:

• Suspension homogeneity
• Long-term particle stability
• Spray plume consistency
• Reduced surfactant concentration
• Nasal tolerability

A successful alternative would require extractables, leachables, impurity and stability assessment across the entire device.

4. Excipient supply-chain resilience

Xhance relies on multiple excipients with established pharmaceutical supply markets. Commercial opportunities include dual sourcing and qualified alternatives for:

• Pharmaceutical-grade carboxymethylcellulose
• Microcrystalline cellulose with controlled particle properties
• Polysorbate 80 with low peroxide levels
• Benzalkonium chloride with consistent preservative potency
• Disodium edetate
• High-purity dextrose

Suppliers able to provide tighter lot-to-lot rheology, low bioburden and validated nasal-use quality could command higher value than commodity excipient suppliers.

5. Pediatric and lower-irritation formulations

Xhance is an adult product. A pediatric or adolescent formulation would require clinical, device-use and safety development. Excipient opportunities would include lower preservative exposure, reduced spray force, smaller dose volume and improved palatability or comfort.

The device may be a larger barrier than the excipient system. Pediatric patients may have difficulty maintaining the required exhalation technique, which limits the value of a formulation-only modification.

6. Combination nasal products

A future product could combine fluticasone propionate with another active ingredient, such as an antihistamine or saline component. The formulation challenges would include:

• Chemical compatibility
• Different solubility profiles
• Distinct dose requirements
• Nasal mucosal tolerability
• Device metering and plume control
• New clinical claims

Combination products could expand the value proposition but would likely require substantial regulatory and patent analysis.

How strong is the Xhance patent estate?

The estate is strongest where the device, active suspension and treatment method operate as a single combination. This structure can make simple formulation substitution insufficient to design around the product.

Patent strength is likely to vary across claim categories:

Claim category	Relative strategic value
Exhalation delivery device	High
Device and nasal deposition method	High
Fluticasone product configuration	Medium to high
Specific excipient combination	Medium
Broad excipient identity claims	Low to medium
Manufacturing know-how	Potentially high but confidential
Indication claims	Medium, subject to label and litigation scope

The weakest design-around strategy would be to copy the same device, active, suspension and dosing profile while changing only a minor excipient. The stronger strategy would combine a materially different device with a distinct formulation and a non-overlapping clinical or regulatory pathway.

What litigation and settlement risks affect generic entry?

Any Paragraph IV challenge to Xhance could create litigation involving both listed patents and product-specific infringement theories. The key disputes would likely concern:

• Whether the proposed formulation falls within the claimed suspension ranges
• Whether the proposed device performs the claimed exhalation function
• Whether the generic label induces infringement of method-of-use claims
• Whether the applicant can lawfully omit protected indications
• Whether the product is pharmaceutically equivalent
• Whether FDA requires additional clinical evidence

Settlement terms could include delayed generic entry, a license date, manufacturing restrictions, or permission to launch a non-infringing formulation. The commercial impact would depend on whether the settlement preserves device-based differentiation or allows a lower-cost equivalent to enter before the full patent estate expires.

What revenue exposure does Xhance create?

Xhance revenue is exposed to several substitution scenarios:

Scenario	Likely commercial effect
Conventional generic steroid sprays	Pressure in lower-severity disease
ANDA for equivalent device product	Highest price and share risk
505(b)(2) exhalation product	Moderate risk through differentiated competition
Biologic expansion	Risk in severe nasal-polyp patients
Preservative-free reformulation	Potential price defense and adherence benefit
Expanded chronic rhinosinusitis use	Volume growth opportunity
Payer restrictions	Reduced access despite clinical differentiation

The 2024 expansion to chronic rhinosinusitis without nasal polyps materially increased the potential patient pool. It also exposed Xhance to a broader comparison set, including standard intranasal corticosteroids and lower-cost generic therapies. [2]

How does Xhance compare with biologic competitors?

Xhance and biologics address overlapping chronic rhinosinusitis populations but occupy different treatment positions.

Product category	Representative products	Primary differentiation
Exhalation-delivered steroid	Xhance	Local delivery to nasal and sinus regions
Conventional intranasal steroid	Generic fluticasone, mometasone, budesonide	Low cost and established use
Anti-IgE biologic	Omalizumab	Systemic targeted therapy
Anti-IL-4/IL-13 biologic	Dupilumab	Severe type 2 inflammation and polyps
Anti-IL-5 biologic	Mepolizumab	Eosinophilic disease and polyps
Surgery	Endoscopic sinus surgery	Mechanical removal and sinus opening

Xhance’s excipient strategy supports a locally delivered product with lower systemic exposure than biologic therapy. Its commercial challenge is demonstrating sufficient incremental value over inexpensive nasal steroids and reserving use in appropriate patients before or alongside costly biologics.

What are the main manufacturing and IP barriers?

The most important manufacturing barriers are:

• Micronization and control of fluticasone particle size
• Uniform suspension manufacture at commercial scale
• Preservation and microbial control
• Pump and actuator dose reproducibility
• Device assembly and airflow calibration
• Container-closure compatibility
• Cleaning and cross-contamination controls
• Stability under shipping and storage conditions

Manufacturing know-how may be difficult to replicate even when the qualitative excipient list is public. A competitor can source the same excipients yet obtain different spray performance because of differences in mixing energy, wetting order, particle-size distribution, polymer hydration, filling conditions or pump components.

What is the best commercial excipient strategy for Xhance?

The strongest near-term strategy is incremental improvement rather than wholesale excipient replacement.

Priority areas are:

1. Qualify dual sources for all critical excipients.
2. Reduce polysorbate oxidation risk through tighter raw-material specifications.
3. Optimize cellulose-polymer rheology for redispersion and pump consistency.
4. Assess preservative-reduced and preservative-free device options.
5. Develop a lower-volume or lower-force presentation for adherence.
6. Protect the formulation through composition, process and device-combination claims.
7. Use comparative deposition and usability data to support premium positioning.
8. Preserve compatibility with the existing approved product where possible.

A reformulation that changes excipients but does not improve deposition, tolerability, adherence or cost is unlikely to create durable commercial value.

Key Takeaways

• Xhance uses a fluticasone propionate suspension with microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, disodium edetate and purified water.
• The formulation is inseparable from the exhalation delivery device.
• The strongest commercial opportunities are preservative reduction, suspension optimization, supply-chain resilience and pediatric-oriented usability.
• A generic competitor faces device, suspension, dose-uniformity, bioequivalence and patent barriers.
• Xhance’s 2024 chronic rhinosinusitis expansion increased market opportunity but also increased competition with low-cost conventional nasal steroids.
• Excipient changes alone are unlikely to avoid combination-product patent claims.
• Biologics create competitive pressure in severe chronic rhinosinusitis with nasal polyps, while conventional generics create the main price threat.
• The most defensible reformulation would combine improved tolerability or adherence with a distinct device and patent strategy.

FAQs

Can Xhance be reformulated without benzalkonium chloride?

Yes, but a preservative-free or reduced-preservative version would require a new microbiological control strategy and may require device changes, stability studies and supplemental FDA review.

Would a different cellulose polymer create a generic Xhance?

Not necessarily. A different polymer may affect suspension behavior, dose delivery and regulatory equivalence. It may also remain within device, formulation or method-of-use patent claims.

Is Xhance a biologic?

No. Xhance is a small-molecule fluticasone propionate product delivered through a specialized nasal device. Biosimilar rules do not apply.

Could a generic manufacturer use the same Xhance excipients?

It could seek to use the same qualitative excipients, but the proposed product would still need to address pharmaceutical equivalence, device performance, bioequivalence and Orange Book patent certifications.

What is the largest excipient opportunity around Xhance?

The largest opportunity is a lower-irritation multidose suspension, potentially with reduced or no benzalkonium chloride, provided the redesigned system preserves microbial safety, dose uniformity and exhalation-assisted deposition.

References

1. U.S. Food and Drug Administration. (2017). Xhance prescribing information.
2. U.S. Food and Drug Administration. (2024). Xhance prescribing information and supplemental approval materials for chronic rhinosinusitis.
3. U.S. Food and Drug Administration. (2023). Dupixent prescribing information.
4. U.S. Food and Drug Administration. (2023). Nucala prescribing information.
5. U.S. Food and Drug Administration. (2023). Xolair prescribing information.